1. Home
  2. RCMT vs KPTI Comparison

RCMT vs KPTI Comparison

Compare RCMT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RCM Technologies Inc.

RCMT

RCM Technologies Inc.

HOLD

Current Price

$18.51

Market Cap

150.7M

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$8.56

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCMT
KPTI
Founded
1971
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
150.7M
148.0M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RCMT
KPTI
Price
$18.51
$8.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$30.00
$22.17
AVG Volume (30 Days)
47.0K
604.4K
Earning Date
03-11-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.71
N/A
Revenue
$309,840,000.00
$146,067,000.00
Revenue This Year
$16.29
$3.55
Revenue Next Year
$6.92
N/A
P/E Ratio
$10.72
N/A
Revenue Growth
13.70
0.57
52 Week Low
$13.18
$3.51
52 Week High
$28.27
$10.38

Technical Indicators

Market Signals
Indicator
RCMT
KPTI
Relative Strength Index (RSI) 27.81 72.22
Support Level $17.26 $5.90
Resistance Level $21.41 $9.94
Average True Range (ATR) 0.74 0.80
MACD -0.32 0.27
Stochastic Oscillator 3.86 78.22

Price Performance

Historical Comparison
RCMT
KPTI

About RCMT RCM Technologies Inc.

RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: